Literature DB >> 8093705

Effect of a single dose of inhaled salmeterol on baseline airway caliber and methacholine-induced airway obstruction in asthmatic children.

A A Verberne1, W C Hop, A B Bos, K F Kerrebijn.   

Abstract

BACKGROUND: Salmeterol is a new inhaled selective beta 2-adrenergic receptor agonist with a long duration of action. We studied the duration of the bronchodilation and the protective effect against methacholine-induced airway obstruction of a single dose of salmeterol in a double-blind, randomized, placebo-controlled, crossover design.
METHODS: Seventeen boys and three girls with mild-to-moderate asthma participated in the study. On two separate days either 50 micrograms salmeterol or placebo was inhaled. FEV1 and PD20 methacholine were determined before and 1, 4, 8, 12, and 24 hours after inhalation.
RESULTS: Salmeterol resulted in a significant bronchodilation compared with placebo, up to 12 hours (p = 0.0001). At 24 hours there was a residual effect that approached significance; mean FEV1 being 8.3% +/- 2.4% above baseline (p = 0.06). Significant protection against airway sensitivity to methacholine after salmeterol inhalation was found at all time points (p < 0.005). Twenty-four hours after administration mean PD20 was still 1.22 +/- 0.29 doubling dose above baseline. No important adverse effects were noted.
CONCLUSION: We conclude that a single dose of 50 micrograms salmeterol in children with asthma gives a long-lasting bronchodilation, exceeding 12 hours, which is comparable to the results in adult studies. The duration of the protection against airway sensitivity to methacholine exceeds 24 hours.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093705     DOI: 10.1016/0091-6749(93)90305-y

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Influence of intranasal steroids during the grass pollen season on bronchial responsiveness in children and young adults with asthma and hay fever.

Authors:  B J Thio; G L Slingerland; A M Fredriks; A F Nagelkerke; R A Scheeren; H J Neijens; J J Roord; J E Dankert-Roelse
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 3.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 4.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Regular treatment with salmeterol for chronic asthma: serious adverse events.

Authors:  Christopher J Cates; Matthew J Cates
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

6.  Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids.

Authors:  Alexander Chuchalin; Loretta Jacques; Lucy Frith
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 7.  Methacholine challenge testing: comparative pharmacology.

Authors:  Beth E Davis; Christianne M Blais; Donald W Cockcroft
Journal:  J Asthma Allergy       Date:  2018-05-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.